Rates of major adverse cardiovascular events and mortality with basal insulin by liraglutide use: a DEVOTE sub-analysis

Cardiovascular (CV) safety profiles for insulin degludec (degludec) and insulin glargine 100 units/mL (glargine U100) were established by the DEVOTE and ORIGIN trials. In the LEADER trial, the glucagon-like peptide 1 analog liraglutide significantly reduced risks of major adverse cardiovascular events (MACE) and mortality vs. placebo in patients with type 2 diabetes (T2D) and high CV risk.